{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:19:15Z","timestamp":1794611955234,"version":"4.9.1"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Therapeutic strategies that target leukemic stem cells (LSCs) provide potential advantages in the treatment of chronic myeloid leukemia (CML). Here, we show that selective blockade of plasminogen activator inhibitor-1 (PAI-1) enhances the susceptibility of CML-LSCs to tyrosine kinase inhibitor (TKI), which facilitates the eradication of CML-LSCs and leads to sustained remission of the disease. We demonstrated for the first time that TGF-\u03b2-PAI-1 axis was selectively augmented in CML-LSCs in the bone marrow (BM), whereby protecting CML-LSCs from TKI treatment. Furthermore, the combined administration of TKI plus a PAI-1 inhibitor, in a mouse model of CML, significantly enhanced the eradication of CML cells in the BM and prolonged the survival of CML mice. The combined therapy of imatinib and a PAI-1 inhibitor prevented the recurrence of CML-like disease in serially transplanted recipients, indicating the elimination of CML-LSCs. Interestingly, PAI-1 inhibitor treatment augmented membrane-type matrix metalloprotease-1 (MT1-MMP)-dependent motility of CML-LSCs, and the anti-CML effect of PAI-1 inhibitor was extinguished by the neutralizing antibody for MT1-MMP, underlining the mechanistic importance of MT1-MMP. Our findings provide evidence of, and a rationale for, a novel therapeutic tactic, based on the blockade of PAI-1 activity, for CML patients.<\/jats:p>","DOI":"10.3324\/haematol.2019.230227","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T14:35:11Z","timestamp":1580394911000},"page":"483-494","source":"Crossref","is-referenced-by-count":32,"title":["Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells"],"prefix":"10.3324","volume":"106","author":[{"family":"Takashi Yahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Abd Aziz Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ken-ichi Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yukari Muguruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kazuhito Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Katsuto Hozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Douglas E. Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Toshio Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kiyoshi Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"20325","unstructured":"Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960; 25:85-109."},{"key":"20326","doi-asserted-by":"crossref","unstructured":"Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243(5405):290-293.","DOI":"10.1038\/243290a0"},{"key":"20327","doi-asserted-by":"crossref","unstructured":"Bartram CR, de Klein A, Hagemeijer A. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983; 306(5940):277-280.","DOI":"10.1038\/306277a0"},{"key":"20328","doi-asserted-by":"crossref","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-2417.","DOI":"10.1056\/NEJMoa062867"},{"key":"20329","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Larson RA, Guilhot F. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10):917-927.","DOI":"10.1056\/NEJMoa1609324"},{"key":"20330","doi-asserted-by":"crossref","unstructured":"Huntly BJP, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005; 5(4):311-321.","DOI":"10.1038\/nrc1592"},{"key":"20331","doi-asserted-by":"crossref","unstructured":"Bhatia R, Holtz M, Niu N. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003; 101(12):4701-4707.","DOI":"10.1182\/blood-2002-09-2780"},{"key":"20332","doi-asserted-by":"crossref","unstructured":"Corbin AS, Agarwal A, Loriaux M. Human chronic meyloid leukemia stem cells insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011; 121(1):396-409.","DOI":"10.1172\/JCI35721"},{"key":"20333","doi-asserted-by":"crossref","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-737.","DOI":"10.1038\/nm0797-730"},{"key":"20334","doi-asserted-by":"crossref","unstructured":"Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H. TGF-as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood. 2009; 113(6):1250-1256.","DOI":"10.1182\/blood-2008-04-146480"},{"key":"20335","doi-asserted-by":"crossref","unstructured":"Yamazaki S, Ema H, Karlsson G. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell. 2011; 147(5):1146-1158.","DOI":"10.1016\/j.cell.2011.09.053"},{"key":"20336","doi-asserted-by":"crossref","unstructured":"Naka K, Hoshii T, Muraguchi T. TGF- -FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-680.","DOI":"10.1038\/nature08734"},{"key":"20337","doi-asserted-by":"crossref","unstructured":"Naka K, Ishihara K, Jomen Y. Novel oral transforming growth factor-signaling inhibitor EW-7197 eradicates CML-initiating cells. Cancer Sci. 2016; 107(2):140-148.","DOI":"10.1111\/cas.12849"},{"key":"20338","doi-asserted-by":"crossref","unstructured":"Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABLexpressing leukemic stem cells. Nat Med. 2006; 12(10):1175-1180.","DOI":"10.1038\/nm1489"},{"key":"20339","doi-asserted-by":"crossref","unstructured":"Krause DS, Fulzele K, Catic A. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013; 19(11):1513-1517.","DOI":"10.1038\/nm.3364"},{"key":"20340","doi-asserted-by":"crossref","unstructured":"Guarnerio J, Mendez LM, Asada N. A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. Nat Commun. 2018; 9(1):66.","DOI":"10.1038\/s41467-017-02427-x"},{"key":"20341","doi-asserted-by":"crossref","unstructured":"Yahata T, Ibrahim AA, Muguruma Y. TGF-\u2013induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche. Blood. 2017; 130(21):2283-2294.","DOI":"10.1182\/blood-2017-02-767384"},{"key":"20342","doi-asserted-by":"crossref","unstructured":"Vagima Y, Avigdor A, Goichberg P. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J Clin Invest. 2009; 119(3):492-503.","DOI":"10.1172\/JCI36541"},{"key":"20343","doi-asserted-by":"crossref","unstructured":"Shirvaikar N, Marquez-Curtis LA, Shaw AR, Turner AR, Janowska-Wieczorek A. MT1- MMP association with membrane lipid rafts facilitates G-CSF-induced hematopoietic stem\/progenitor cell mobilization. Exp Hematol. 2010; 38(9):823-835.","DOI":"10.1016\/j.exphem.2010.05.002"},{"key":"20344","doi-asserted-by":"crossref","unstructured":"Ibrahim AA, Yahata T, Muguruma Y, Miyata T, Ando K. Blockade of plasminogen activator inhibitor-1 empties bone marrow niche sufficient for donor hematopoietic stem cell engraftment without myeloablative conditioning. Biochem Biophys Res Commun. 2019; 516(2):500-505.","DOI":"10.1016\/j.bbrc.2019.06.076"},{"key":"20345","doi-asserted-by":"crossref","unstructured":"Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012; 227(2):493-507.","DOI":"10.1002\/jcp.22783"},{"key":"20346","doi-asserted-by":"crossref","unstructured":"Placencio VR, DeClerck YA. Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Res. 2015; 75(15):2969-2974.","DOI":"10.1158\/0008-5472.CAN-15-0876"},{"key":"20347","doi-asserted-by":"crossref","unstructured":"Van De Craen B, Declerck PJ, Gils A. The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI- 1 inhibition in vivo. Thromb Res. 2012; 130(4):576-585.","DOI":"10.1016\/j.thromres.2012.06.023"},{"key":"20348","doi-asserted-by":"crossref","unstructured":"Yamaoka N, Murano K, Kodama H. Identification of novel plasminogen activator inhibitor-1 inhibitors with improved oral bioavailability: structure optimization of Nacylanthranilic acid derivatives. Bioorg Med Chem Lett. 2018; 28(4):809-813.","DOI":"10.1016\/j.bmcl.2017.11.016"},{"key":"20349","doi-asserted-by":"crossref","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990; 247(4944):824-830.","DOI":"10.1126\/science.2406902"},{"key":"20350","doi-asserted-by":"crossref","unstructured":"Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR\u2013ABL1. Nat Genet. 2000; 24(1):57-60.","DOI":"10.1038\/71691"},{"key":"20351","doi-asserted-by":"crossref","unstructured":"Koschmieder S, G\u00f6ttgens B, Zhang P. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005; 105(1):324-334.","DOI":"10.1182\/blood-2003-12-4369"},{"key":"20352","doi-asserted-by":"crossref","unstructured":"Saito Y, Uchida N, Tanaka S. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010; 28(3):275-280.","DOI":"10.1038\/nbt.1607"},{"key":"20353","doi-asserted-by":"crossref","unstructured":"Medyouf H. The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. Blood. 2017; 129(12):1617-1626.","DOI":"10.1182\/blood-2016-11-696070"},{"key":"20354","doi-asserted-by":"crossref","unstructured":"Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12(10):1167-1174.","DOI":"10.1038\/nm1483"},{"key":"20355","doi-asserted-by":"crossref","unstructured":"Neering SJ, Bushnell T, Sozer S. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007; 110(7):2578-2585.","DOI":"10.1182\/blood-2007-02-073031"},{"key":"20356","doi-asserted-by":"crossref","unstructured":"Lapidot T, Petit I. Current understanding of stem cell mobilization. Exp Hematol. 2002; 30(9):973-981.","DOI":"10.1016\/S0301-472X(02)00883-4"},{"key":"20357","unstructured":"Lapid K, Glait-Santar C, Gur-Cohen S, Canaani J, Kollet O, Lapidot T. Egress and mobilization of hematopoietic stem and progenitor cells: a dynamic multi-facet process.p1-37."},{"key":"20358","doi-asserted-by":"crossref","unstructured":"Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood. 2014; 123(9):1361-1371.","DOI":"10.1182\/blood-2013-11-538694"},{"key":"20359","doi-asserted-by":"crossref","unstructured":"Chen Y, Kelm RJ, Budd RC, Sobel BE, Schneider DJ. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem. 2004; 92(1):178-188.","DOI":"10.1002\/jcb.20058"},{"key":"20360","doi-asserted-by":"crossref","unstructured":"Placencio VR, Ichimura A, Miyata T, DeClerck YA. Small molecule inhibitors of plasminogen activator inhibitor-1 elicit antitumorigenic and anti-angiogenic activity. PLoS One. 2015; 10(7):e0133786.","DOI":"10.1371\/journal.pone.0133786"},{"key":"20361","doi-asserted-by":"crossref","unstructured":"Mashiko S, Kitatani K, Toyoshima M. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther. 2015; 16(2):253-260.","DOI":"10.1080\/15384047.2014.1001271"},{"key":"20362","doi-asserted-by":"crossref","unstructured":"Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002; 30(9):973-981.","DOI":"10.1016\/S0301-472X(02)00883-4"},{"key":"20363","doi-asserted-by":"crossref","unstructured":"Borthakur G, Kantarjian H, Wang X. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008; 113(11):3181-3185.","DOI":"10.1002\/cncr.23927"},{"key":"20364","doi-asserted-by":"crossref","unstructured":"Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007; 67(3):1113-1120.","DOI":"10.1158\/0008-5472.CAN-06-2014"},{"key":"20365","doi-asserted-by":"crossref","unstructured":"Uy GL, Rettig MP, Motabi IH. A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012; 119(17):3917-3924.","DOI":"10.1182\/blood-2011-10-383406"},{"key":"20366","doi-asserted-by":"crossref","unstructured":"Beider K, Darash-Yahana M, Blaier O. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther. 2014; 13(5):1155-1169.","DOI":"10.1158\/1535-7163.MCT-13-0410"},{"key":"20367","doi-asserted-by":"crossref","unstructured":"Godavarthy PS, Kumar R, Herkt SC. The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL\/TAL1 - CD44 axis. Haematologica. 2020; 105(1):136-147.","DOI":"10.3324\/haematol.2018.212365"},{"key":"20368","doi-asserted-by":"crossref","unstructured":"Izuhara Y, Takahashi S, Nangaku M. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol. 2008; 28(4):672-677.","DOI":"10.1161\/ATVBAHA.107.157479"},{"key":"20369","doi-asserted-by":"crossref","unstructured":"Izuhara Y, Yamaoka N, Kodama H. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 2010; 30(5):904-912.","DOI":"10.1038\/jcbfm.2009.272"},{"key":"20370","doi-asserted-by":"crossref","unstructured":"Eren M, Boe AE, Murphy SB. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci U S A. 2014; 111(19):7090-7095.","DOI":"10.1073\/pnas.1321942111"},{"key":"20371","doi-asserted-by":"crossref","unstructured":"Boe AE, Eren M, Murphy SB. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates N\u03c9-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation. 2013; 128(21):2318-2324.","DOI":"10.1161\/CIRCULATIONAHA.113.003192"},{"key":"20372","doi-asserted-by":"crossref","unstructured":"Pelisch N, Dan T, Ichimura A. Plasminogen activator inhibitor-1 antagonist TM5484 attenuates demyelination and axonal degeneration in a mice model of multiple sclerosis. PLoS One. 2015; 10(4):e0124510.","DOI":"10.1371\/journal.pone.0124510"},{"key":"20373","doi-asserted-by":"crossref","unstructured":"Ibrahim AA, Yahata T, Onizuka M. Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration. Stem Cells. 2014; 32(4):946-958.","DOI":"10.1002\/stem.1577"},{"key":"20374","doi-asserted-by":"crossref","unstructured":"Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE. PAI-1 is a critical regulator of FGF23 homeostasis. Sci Adv. 2017; 3(9):e1603259.","DOI":"10.1126\/sciadv.1603259"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9639\/70538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9639\/70539","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9639\/70538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:55:53Z","timestamp":1794045353000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.230227","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}